Botulinum toxin in Urology

Conclusions There is good quality evidence to support the use of intradetrusor BTA in patients with detrusor overactivity both neurogenic and idiopathic as well as in overactive bladder and bladder pain syndrome. The evidence with regards to detrusor sphincter dyssynergia, dysfunctional voiding and benign prostatic hyperplasia is less robust. Liposomal BTA delivery may present an attractive future option in Urological disorders.
Source: Apollo Medicine - Category: Journals (General) Source Type: research